Last updated: February 13, 2026
Which therapeutic category does NDC 66758-0146 belong to?
NDC 66758-0146 is identified as Ocrevus (ocrelizumab), a monoclonal antibody used primarily in the treatment of multiple sclerosis (MS). It is approved for relapsing forms of MS and primary progressive MS.
Market size and demand for Ocrevus
The global multiple sclerosis (MS) treatment market was valued at approximately $23 billion in 2021.[1] Ocrevus holds a significant share within this space, driven by the following factors:
- Market penetration: As one of the few anti-CD20 monoclonal antibodies approved for both relapsing and primary progressive MS.
- Patient population: Estimated 2.8 million MS patients worldwide as of 2020.[2]
- Pricing strategies: Typically priced between $65,000 and $70,000 annually per patient in the US.[3]
Competitive landscape
Key competitors include:
- Novartis Gilenya (fingolimod): $70,000/year.
- Biogen Avonex (interferon beta-1a): ~$65,000/year.
- Roche's Rituxan (rituximab): Off-label use for MS, lower cost, but not FDA-approved for MS in the US.
Ocrevus’s advantages include approval for both relapsing MS and primary progressive MS, providing a broader market scope, especially as primary progressive MS accounts for about 10-15% of all MS cases.[4]
Pricing trends and projections
Current prices:
In the US, Ocrevus is listed at approximately $65,000–$70,000 annually per patient.[3] Variability exists based on insurance coverage and discounts negotiated by healthcare providers.
Pricing pressures:
- Patent exclusivity protects Ocrevus until at least 2030.
- Introduction of biosimilars for rituximab (a related antibody) could exert pricing pressures on Ocrevus.
- Competitive landscape shifts and healthcare policy adjustments may influence future pricing.
Projections up to 2027:
- The MS market growth rate is estimated at 4-5% annually.[1]
- Ocrevus’s market share is projected to expand as it continues to gain approval in more regions and indications.
- Prices could decline by 10-15% over the next five years due to increased competition and biosimilar entry, barring regulatory or patent extensions.
Pricing assumptions for future scenarios
| Year |
Estimated Price Range |
Notes |
| 2023 |
$65,000–$70,000 |
Current US list price |
| 2025 |
$58,500–$63,000 |
10% decline, new biosimilar competition |
| 2027 |
$55,000–$60,000 |
Continued price adjustments |
Regulatory and policy factors
- Patent protection: Extends until approximately 2030.
- European pricing: Generally lower than US prices; discounts of 20-30% are common.
- Value-based pricing: An emerging trend where reimbursement depends on treatment outcomes, potentially influencing future pricing.
Summary
- The MS treatment market is growing, driven by larger patient populations and expanding indications.
- Ocrevus maintains a premium pricing position, with US prices near $65,000 to $70,000 annually per patient.
- Future prices are likely to decline modestly due to biosimilar competition and policy changes, with a potential decrease of 10-15% over five years.
- Market and regulatory dynamics suggest continued revenue stability until patent expiry.
Key Takeaways
- Ocrevus dominates the dual-indication MS market with a current price of approximately $65,000–$70,000 per year.
- Market growth and a broad patient demographic support ongoing revenues, but biosimilars and policy shifts pressure pricing.
- Price projections indicate modest declines by 2027, with prices possibly dropping to $55,000–$60,000 due to competition.
- Patent protection limits generic entry until ~2030, supporting revenue stability for now.
- The expanding MS patient pipeline and increasing awareness could sustain demand, offsetting some pricing downward trends.
FAQs
1. What factors influence the price of Ocrevus in different regions?
Pricing varies due to healthcare reimbursement policies, local regulations, negotiated discounts, and market competition. The US typically has higher prices, with discounts negotiated by insurers and pharmacy benefit managers.
2. How does biosimilar competition impact Ocrevus pricing?
Biosimilars for rituximab, a similar anti-CD20 antibody, may lead to reduced prices in off-label uses and could influence Ocrevus pricing, especially if biosimilars gain approval and market share.
3. When does patent expiry threaten Ocrevus’s exclusivity?
Patent protection is expected through 2030, after which biosimilars could enter the market, increasing price competition.
4. What are the main indications for Ocrevus?
Relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making it suitable for broad patient segments.
5. How is the MS treatment market expected to evolve?
It is projected to grow at 4-5% annually through 2027, driven by increasing diagnoses and broader treatment options, thereby supporting sustained demand for drugs like Ocrevus.
References
[1] MarketWatch, "Global Multiple Sclerosis Treatment Market," 2022.
[2] National MS Society, "MS Prevalence Data," 2020.
[3] GoodRx, "Ocrevus Pricing," 2023.
[4] National Institutes of Health, "Types of Multiple Sclerosis," 2022.
